Context • the arise of the advanced and enhanced cancer remedies has extended the life expectancy of many patients who nevertheless survive now to fight the numerous concomitant long-term side effects. trastuzumab had an accelerated FDA approval since it drastically improved the prognosis of hER-2 positive (hER-2+) breast cancer (BC) convalescents. Its cardiotoxic effect was noticed early during the trials and many guidelines were established to insure its early detection and treatment. Recent studies showed a controversial variation of compliance to the cardiac surveillance guidelines and a need for further testing to evaluate the vitality of increased monitoring.
Objective • Study the compliance to the cardiac surveillance guidelines at our institution for hER-2+ non-metastatic breast cancer (NMBC) patients treated with trastuzumab.
Methods • the data of 99 patients diagnosed with hER-2+ NMBC treated with trastuzumab was collected and analyzed retrospectively for echocardiographic results and dates. the dates were evaluated looking for the presence or absence of a comparable timeline with the guidelines within a range of 21 days. the presence of cardiotoxic events was indicated to analyze its incidence and timing to be able to deduce a need for closer monitoring. Patients were then analyzed according to the type of associated systemic therapy and treating physicians.
Keywords: cardiac surveillance; guidelines; Trastuzumab; cardiotoxicity; compliance; real life